No Data
No Data
Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
Maxim Group Maintains Avenue Therapeutics(ATXI.US) With Buy Rating
Maxim Group analyst Jason McCarthy maintains $Avenue Therapeutics(ATXI.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 29.1% and a total average return of -16.8% o
Express News | Avenue Therapeutics: Maxim Group lowered its target price to $12 to reflect a 1-for-75 stock split.
Express News | Avenue Therapeutics Inc : Maxim Group Cuts Target Price to $12 From $56.25 to Reflect 1-for-75 Reverse Stock Split
Avenue Therapeutics: Received notice from NASDAQ that the company complies with all requirements set out in NASDAQ Listing Rule 5550 (B) (1)
Avenue Therapeutics: Received notice from NASDAQ that the company complies with all requirements set out in NASDAQ Listing Rule 5550 (B) (1)
Express News | Avenue Therapeutics: Received Notice From Nasdaq Notifying Co Is in Compliance With All Requirement Set Forth in Nasdaq Listing Rule 5550(B)(1)
No Data